**ibrexafungerp**

**Brexafemme**

*Pharmaceutical company: Scynexis, Inc.*

*Pharmacologic classification: Triterpenoid antifungal*

*Therapeutic classification: Antifungal*

---

**AVAILABLE FORMS**

*Tablets: 150 mg*

**INDICATIONS AND DOSAGES**

*Treatment of patients with vulvovaginal candidiasis*

*Adults and postmenarchal pediatric females:* 300 mg (two 150-mg tablets) PO administered approximately 12 hours apart (in the morning and in the evening) for one day, for a total daily dosage of 600 mg (total of 4 tablets for one course of therapy).

*Adjust-a-dose:* If taking a concomitant strong CYP3A inhibitor, administer one 150-mg tablet approximately 12 hours apart (in the morning and in the evening) for 1 day (total of 2 tablets for one course of therapy).

**CONTRAINDICATIONS AND CAUTIONS**

- Contraindicated in pregnancy or in patients hypersensitive to the drug or its components.
- Safety has not been established in premenarchal pediatric females.
- *Dialyzable drug: No.*

**PREGNANCY-LACTATION-REPRODUCTION**

- This drug may cause fetal harm; use is contraindicated in pregnancy.
- Verify the pregnancy status in females of reproductive potential prior to initiating treatment.
- If this drug is inadvertently administered during pregnancy or if pregnancy is detected within 4 days after a patient receives the drug, pregnant women exposed to the drug and health care providers should report pregnancies to Scynexis, Inc. at 1-888-982-SCYX (7299).
- There is no information regarding this drug’s presence in human breast milk; weigh the risk to the breastfed child.
- Advise females of reproductive potential to use effective contraception during treatment and for 4 days after the last dose.

**INTERACTIONS**

**Drug-drug. Strong CYP3A inhibitors (ketoconazole, itraconazole):** May significantly increase ibrexafungerp level; reduce ibrexafungerp dosage.

**Strong/moderate CYP3A inducers (rifampin, carbamazepine, phenytoin, long-acting barbiturates, bosentan, efavirenz, or etravirine):** May significantly reduce ibrexafungerp level; avoid use together.

**Drug-herb. St. John’s wort:** May significantly reduce ibrexafungerp level; discourage use together.

**ADVERSE REACTIONS**

**CNS:** dizziness.

**GI:** diarrhea, nausea, abdominal pain, vomiting, flatulence.

**GU:** dysmenorrhea, vaginal bleeding.

**Hepatic:** elevated transaminases.

**Musculoskeletal:** back pain.
Skin: rash.
Other: hypersensitivity reaction.

Reactions in bold italics are *life-threatening.*